Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01A: Pembrolizumab With or Without Chemotherapy in Treatment-Naive Stage IV NSCLC
NCT04165070Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Primary completion
- Feb 2032
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of vibostolimab, boserolimab, mk-4830, rolistobart, ifinatamab deruxtecan and 1 more in non-small cell lung cancer (NSCLC) (11 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate at 24 months, Adverse Events at 27 months and 2 more. Started Dec 2019; status: recruiting.
02
Drugs
vibostolimabboserolimabmk-4830rolistobartifinatamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04165070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165070.